ArticleCureus2026
Trastuzumab-Induced Pneumonitis: A Rare but Potentially Severe Pulmonary Complication.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is widely used in the treatment of HER2-positive breast cancer. Although generally well tolerated, trastuzumab has been rarely associated with pulmonary toxicity, including interstitial pneumonitis, a potentially life-threatening complication that may progress to acute respiratory distress syndrome (ARDS). We report the case of a 75-year-old woman with HER2-positive pleomorphic lobular breast carcinoma treated with docetaxel, carboplatin, trastuzumab, and pertuzumab. Shortly after her fifth chemotherapy cycle, she developed acute respiratory failure characterized by severe hypoxemia. Chest computed tomography revealed bilateral ground-glass opacities with interstitial thickening and pleural effusions. Extensive infectious workup, including respiratory viral panels and bronchial cultures, was negative. Given the temporal relationship with trastuzumab exposure and exclusion of alternative diagnoses, trastuzumab-induced pneumonitis was suspected. The patient progressed to severe ARDS requiring invasive mechanical ventilation and prone positioning. High-dose systemic corticosteroid therapy resulted in significant initial clinical and gasometric improvement. However, her course was complicated by ventilator-associated pneumonia due to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.